InvestDashboard.com



Taro Pharmaceutical Industries Ltd. (TARO)



$92.28
52 Week Low
$116.85
2017-04-28 14:31:27 MDT
$150.75
52 Week High

Basic Info

Healthcare
Sector
Drug Manufacturers - Other
Industry
NYSE
Stock Exchange
Israel
Country

Market Cap: $4,740,000,000Mid Cap (Between $2B and $10B)
Analyst Recommendation:2Analysts say: Buy. (1=Strong Buy, 5=Strong Sell)
Beta: 0.36 Low Volatility Stock (beta under 1). Stock will go up less when the market goes up, and go down less when the market goes down. Beta of 1 means stock would match the S&P 500 Index.

Fundamentals

ForwardPE: Unknown
5 Yr Est Growth: -12.95 %
Yield: 0.00%
PEG-Y Ratio: N/A
Unknown PEG-Y ratio

Technicals

% Above 50 DayMA: 0.87%
% Above 200 DayMA: 7.62%
TARO Performance 52 Weeks: -19.78%
S&P 500 Performance 52 Weeks: 12.50%
Uptrend is still intact: TARO is above both 50 and 200 day Moving Averages. There is hope because 50 Day MA is still above 200 Day MA. Stock is closer to 52 Week Low than 52 Week High.
TARO underperforming S&P 500 by -32.28% the last 52 Weeks.

Profile


More Valuation

Price To Book: 2.37
Great Value. Low Price to Book means better value.
EV to EBITDA: 5.95
Great Value! A low EV to EBITDA ratio is great. Ideally, under 10. Under 17 is okay.

More Info

Field Value Average Comments
% Held By InsidersN/A 17.28%Unknown.
% Held By InstitutionsN/A 62.07%Unknown.
Short % Of Float18.62% 07.02% Shorted by greater than average percent. Investors and traders do not believe in stock. But watch out for short squeezes pushing stock upwards.
Debt to EquityN/A 1.08Unknown.
Profit Margin %51.51%-00.18% Profit Margin is better than the average! Good job.
Operating Margin %62.78%-05.28% Operating Margin greater than average percent. Good.
Return on Equity %25.89%-08.79% Return on Equity greater than average percent. Good.
Return on Assets %17.23%-01.29% Return on Assets greater than average percent. Good.
Revenue Per Employee $673,809.52 $883,096.70 Less than average Revenue Per Employee. This stock (or industry) might not be as efficient as others? Each industry might have a different standard.
Price to Cash 4.32 5.52 Lower than average Price to Cash. Meaning that the company has a higher percentage of cash as a percent of price. Cash can be good to cushion company during hard times, and as a potential source for buyouts or investments. However, some activists want the cash to be used by a company to buy its own stock, or to increase their dividend, or to invest the money.
CPEGY Ratio N/A 2.26Unknown.

Quick Thoughts

PROS:
  1. Analysts like this stock: 2 (1=Strong Buy, 5=Strong Sell)

  2. Stock is Above Short Term 50DMA: 0.87%

  3. Stock is Above Long Term 200DMA: 7.62%

  4. Price to Cash Ratio (4.32) is less than average. Good. Company has more cash as percentage of price than other companies.

  5. Price to Book is under 5: 2.37

  6. Better than average EV/EBITDA: 5.95

  7. Profit Margin is positively good: 51.51%

  8. Operating Margin is positively good: 62.78%

  9. Return on Equity is positively good: 25.89%

  10. Return on Assets is positive: 17.23%

CONS:
  1. Less than Average 5 Yr Est Growth: -12.95 %

  2. Stock underperforming S&P 500 over last 52 weeks: -32.28%

  3. Shorted more than average: 18.62%


Headlines


Stock Chart


InvestDashboard.com TARO: Taro Pharmaceutical Industries Ltd.

This page updated Thu Feb 1 22:00:01 MST 2018.